Vir Biotechnology Financials

VIR Stock  USD 9.65  0.07  0.73%   
Based on the key measurements obtained from Vir Biotechnology's financial statements, Vir Biotechnology is not in a good financial situation at this time. It has a very high odds of going through financial crisis in March. At this time, Vir Biotechnology's Non Current Liabilities Total is relatively stable compared to the past year. As of 02/16/2025, Capital Surpluse is likely to grow to about 1.9 B, while Total Current Liabilities is likely to drop slightly above 194.6 M. Key indicators impacting Vir Biotechnology's financial strength include:
Current ValueLast YearChange From Last Year 10 Year Trend
Current Ratio8.1110.41
Significantly Down
Slightly volatile
The essential information of the day-to-day investment outlook for Vir Biotechnology includes many different criteria found on its balance sheet. An individual investor should monitor Vir Biotechnology's cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Vir Biotechnology.

Net Income

(671.95 Million)

  

Vir Biotechnology Stock Summary

Vir Biotechnology competes with CureVac NV, Krystal Biotech, Propanc Biopharma, Blueprint Medicines, and Amylyx Pharmaceuticals. Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California. Vir Biotechnology operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 444 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
ISINUS92764N1028
CUSIP92764N102
LocationCalifornia; U.S.A
Business Address1800 Owens Street,
SectorBiotechnology
IndustryHealth Care
BenchmarkDow Jones Industrial
Websitewww.vir.bio
Phone415 906 4324
CurrencyUSD - US Dollar

Vir Biotechnology Key Financial Ratios

Vir Biotechnology Key Balance Sheet Accounts

202020212022202320242025 (projected)
Total Assets918.8M2.0B2.8B1.9B2.2B1.3B
Other Current Liab83.9M226.4M469.7M91.2M104.9M147.1M
Other Liab28.9M36.3M47.6M89.3M102.6M107.8M
Net Tangible Assets371.3M666.1M1.4B2.0B2.3B2.4B
Net Debt(370.0M)(214.3M)(720.7M)(117.0M)(105.3M)(110.6M)
Retained Earnings(667.2M)(138.6M)377.2M(237.8M)(273.5M)(287.2M)
Accounts Payable5.1M6.5M6.4M6.3M7.3M6.5M
Cash436.6M347.8M848.6M241.6M277.8M348.8M
Other Assets77.7M9.8M21.2M1.01.151.09
Capital Surpluse14.7M793.1M1.4B1.6B1.8B1.9B
Other Current Assets53.1M81.6M117.0M24.9M28.6M47.6M
Total Liab201.9M522.4M724.1M328.8M378.1M401.8M
Net Invested Capital716.9M1.4B2.1B1.6B1.8B941.7M
Total Current Assets772.4M1.6B2.5B1.6B1.8B1.1B
Net Working Capital673.3M1.2B2.0B1.4B1.6B929.9M
Short Term Debt3.6M3.9M4.1M12.9M14.8M15.5M
Intangible Assets33.8M33.3M32.8M22.6M20.3M26.4M

Vir Biotechnology Key Income Statement Accounts

The reason investors look at the income statement is to determine what Vir Biotechnology's earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
202020212022202320242025 (projected)
Tax Provision54K21.2M238.4M(58.3M)(67.1M)(63.7M)
Net Interest Income2.8M439K28.1M82.4M94.8M99.5M
Interest Income2.8M439K28.1M82.4M94.8M99.5M
Interest Expense8.0M3.8M272.9M183.1M210.6M221.1M
Total Revenue76.4M1.1B1.6B86.2M99.1M94.2M
Gross Profit76.4M1.0B1.4B83.4M95.9M91.1M
Operating Income(297.0M)276.9M833.1M(684.3M)(787.0M)(747.6M)
Ebit(298.7M)408.8M817.6M(684.3M)(787.0M)(747.6M)
Research Development302.4M448.0M474.6M589.7M678.1M712.0M
Ebitda514.3M420.8M833.1M(664.9M)(764.6M)(726.4M)
Cost Of Revenue301.6M65.9M146.3M2.8M2.5M2.4M
Income Before Tax(298.6M)549.8M754.3M(628.2M)(722.4M)(686.3M)
Net Income(298.7M)528.6M515.8M(615.1M)(707.3M)(672.0M)
Income Tax Expense(54K)21.2M238.4M(13.1M)(15.0M)(14.3M)

Vir Biotechnology Key Cash Accounts

202020212022202320242025 (projected)
Investments(3.5M)(119.0M)(1.2B)116.3M104.7M109.9M
Change In Cash328.7M(88.1M)504.6M(606.7M)(546.0M)(518.7M)
Free Cash Flow(197.5M)(69.4M)1.6B(800.4M)(920.4M)(874.4M)
Depreciation5.4M5.8M6.8M19.5M22.4M23.5M
Other Non Cash Items45.2M(52.6M)388.4M11.2M12.8M12.2M
Capital Expenditures6.5M21.8M68.0M21.6M24.8M21.7M
Net Income(298.7M)528.6M515.8M(615.1M)(707.3M)(672.0M)
End Period Cash Flow451.5M363.4M868.0M261.3M300.5M363.8M
Change To Netincome32.3M45.2M46.4M475.3M546.6M573.9M

Vir Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Vir Biotechnology's current stock value. Our valuation model uses many indicators to compare Vir Biotechnology value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Vir Biotechnology competition to find correlations between indicators driving Vir Biotechnology's intrinsic value. More Info.
Vir Biotechnology is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Vir Biotechnology's Return On Equity is relatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Vir Biotechnology by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Vir Biotechnology Systematic Risk

Vir Biotechnology's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Vir Biotechnology volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on Vir Biotechnology correlated with the market. If Beta is less than 0 Vir Biotechnology generally moves in the opposite direction as compared to the market. If Vir Biotechnology Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Vir Biotechnology is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Vir Biotechnology is generally in the same direction as the market. If Beta > 1 Vir Biotechnology moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Vir Biotechnology Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Vir Biotechnology's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Vir Biotechnology growth as a starting point in their analysis.

Price Earnings To Growth Ratio

0.0122

At this time, Vir Biotechnology's Price Earnings To Growth Ratio is relatively stable compared to the past year.

Vir Biotechnology February 16, 2025 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Vir Biotechnology help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Vir Biotechnology. We use our internally-developed statistical techniques to arrive at the intrinsic value of Vir Biotechnology based on widely used predictive technical indicators. In general, we focus on analyzing Vir Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Vir Biotechnology's daily price indicators and compare them against related drivers.

Additional Tools for Vir Stock Analysis

When running Vir Biotechnology's price analysis, check to measure Vir Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vir Biotechnology is operating at the current time. Most of Vir Biotechnology's value examination focuses on studying past and present price action to predict the probability of Vir Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vir Biotechnology's price. Additionally, you may evaluate how the addition of Vir Biotechnology to your portfolios can decrease your overall portfolio volatility.